



2020 ASP Forum at “2020 ASP Forum and Cosentyx Grand Ceremony”

Date	December 26, 2020 (Sat)
Venue	Fuli Hotel, Xi’an, China
President	WANG Gang, M.D. & Ph.D. (Chairman and Professor, Department of Dermatology, Xijing Hospital, Fourth Military Medical University & The Vice President of the ASP)
Secretary	FAN Pingshen, M.D. & Ph.D. (Associate Professor, Department of Dermatology, Xijing Hospital, Fourth Military Medical University & The Director and the Secretary in China of the ASP)
Organization	Department of Dermatology at Xijing Hospital
Cooperation	The Asian Society for Psoriasis (The ASP)
Participants	About 850 persons (Onsite and Online)
Co-sponsored	Novartis Pharma K.K., China

Reporter

FAN Pingshen, M.D. & Ph.D. (The Director and the Secretary in China of the ASP)

The forum invited 6 experts of psoriasis from home and abroad, to bring the topics of Psoriasis treatment with Biologics. Dr. WANG Gang (The Vice President of the ASP, China), Dr. MABUCHI Tomotaka (The Vice President of the ASP, Japan), Dr. CHOE Yong Beom (The Director and the Secretary in Korea of the ASP, Korea) and Dr. TASI Dino (The Vice President and the Secretary in Chinese Taipei of the ASP, Chinese Taipei) shared “Positioning and Challenges in the Future for the Treatment with Biologics” in different countries separately. And Dr. YAMAMOTO Toshiyuki (The Director of the ASP, Japan) introduced “2019 PsA Guideline”. 100 psoriasis experts attended the forum on site and was also watched by 750 audiences online.

Thanks to the guidance of Dr. OZAWA Akira (The President of the ASP, Japan) and Prof. Gang Wang as well as the unconditional support and contribution of participating experts, this forum successfully stimulates the academic exchange of Asian dermo-society which was well appreciated by participants.

Prof. Fan Pingshan (The Director and the Secretary in China of the ASP, China) introduced the Council members of the Asian Society for Psoriasis, and the history of the ASP. The purpose of the society is to promote international academic exchanges and to facilitate cooperation. The Asian Society for Psoriasis is also a young international academic organization, hoping to organize more dermatologists together and contribute to the treatment for patients with psoriasis.

Dr. WANG Gang introduced the positioning of biological agents in the treatment of psoriasis in China and the common problems and counter measures in the application of biological agents. The emergence of biological agents is a revolutionary progress in the treatment of psoriasis. In the process of clinical diagnosis and treatment, appropriate biological agents should be selected according to the specific situation of patients. At present, the indication of biologics on the market is moderate-to-severe plaque psoriasis. How to use biologics is the focus and hot spot at present, which is worthy careful thinking so as to make a more suitable choice for patients.

Dr. MABUCHI Tomotaka introduced multicenter studies and genetic studies, and pathogenesis of psoriasis in



Japan. He also introduced the existing treatment methods of psoriasis in Japan which include 10 kinds of biologics such as Secukinumab and Etanercept. According to the current Japanese guidelines for the treatment of psoriasis, in order to ensure the safety of usage, detection of infection should be carried out before and after the use of biologics. Dr. Mabuchi also introduced Japan’s public health care system. At present, Biologic treatment has been covered by NHS in Japan. The reimbursement is determined by patients’ age and income. Most people only need to pay 30% of the treatment cost. And weight-adjusted dosage might be another choice for patients under 60kg.

Dr. CHOE Yong Beom introduced in detail the considerations for the selection of different biological agents, which is of great reference value in clinical work. South Korea is also a country with NHS, which adopts a three-level hospital medical system, mainly receiving critically ill patients. The reimbursement rate can reach 50%, and the reimbursement rate of psoriasis can reach a higher rate through rare disease reimbursement method. We need to continue to explore the selection of biologics, indications and related safety issues. Although the proportion of medical insurance reimbursement is high in South Korea, the indications for biologics approved by medical insurance are relatively strict.

Dr. TSAI Dino introduced the current situation and challenges of the treatment of psoriasis in special population, including pediatric and pregnant patients. Dr. TSAI shared with us his valuable clinical experience in treating these special patients. At the same time, Dr. Cai also mentioned that Secukinumab indications of psoriasis in children has been approved in European and United States in 2020. Dr. Cai pointed out that the treatment of special groups is a situation that dermatologists will encounter, and the basis of all is the trust between doctors and patients.

Dr. YAMAMOTO Toshiyuki introduced the 2019 PsA Guideline of Japan. His speech reminds us to focus deeper and kindlier than just examining the surface of the skin. PsA interprets the essence of “Beyond the Skin Surface”. Dr. YAMAMOTO shared the characteristics of Japanese patients with PsA, compared EULAR/GRAPPA recommendation with Japanese recommendation and displayed the common role of dermatologists in the treatment of PsA in Japan. He also pointed out that Guideline is based on the evidence available at the time of development, therefore should be updated along with new data such as real-world efficacy and long-term data of safety.





2020 ASP FORUM AND COSENTYX GRAND CEREMONY

Dec.26th 2020 Hilton Xi 'an Fuli Hotel

🕒 Time	📄 Topic	👤 Speaker
08:30-08:35	Opening	
08:35-08:40	Welcome speech	Prof.WANG Gang / Prof.Akira OZAWA
08:40-08:55	Introduction of ASP	Prof.FAN Pingshen
08:55-09:25	Positioning and Challenges in the Future for the Treatment with Biologics in Psoriasis - China	Prof.WANG Gang
09:25-09:55	Positioning and Challenges in the Future for the Treatment with Biologics in Psoriasis - Japan	Prof.Tomotaka MABUCHI
09:55-10:10	Break	
10:10-10:40	Positioning and Challenges in the Future for the Treatment with Biologics in Psoriasis - Korea	Prof.Yong Beom CHOE
10:40-11:10	Positioning and Challenges in the Future for the Treatment with Biologics in Psoriasis - Taiwan	Prof.Dino TSAI
11:10-12:10	Interpretation of Japanese Guidance for the Use of Biologics for PsA (the 2019 version) Panel Discussion	Prof.Toshiyuki YAMAMOTO / Prof.Akira OZAWA / Prof.WANG Gang / Prof.Tomotaka MABUCHI / Prof.Yong Beom CHOE / Prof.Dino TSAI / Prof.Toshiyuki YAMAMOTO





中外大咖面对面


Prof. Gang WANG
 Prof. Akira OZAWA
 Prof. Tomotaka MABUCHI
 Prof. Dino TSAI
 Prof. Toshiyuki YAMAMOTO

WITH COSENTYX
 所见·净是美好
 可善挺



WITH COSENTYX
所见·净是美好
 2020亚洲银屑病学会高峰论坛暨可善挺年终盛典
 2020 ASP FORUM AND COSENTYX GRAND CEREMONY







Prof. Dino TSAI

Psoriasis Clinic, Taiwan Adventist Hospital
 Pediatric and Obstetric Dermatology Clinic, Dianthus Medical Group
 Psoriasis Clinic, Dr. Huang Dermatology Clinic
 Psoriasis Clinic, Taiwan Adventist Hospital
 International Fellow, American Academy of Dermatology(AAD)
 Member, Taiwan Dermatological Association(TDA), Japanese Society
 for Psoriasis Research (JSPR), Japanese Society of Pediatric
 Dermatology, Society for Pediatric Dermatology (SPD)

Prof. Dino TSAI
 Psoriasis Clinic, Taiwan Adventist
 Hospital

COSENTIX
 可善挺 淨是美好

2020 ASP FORUM

**Interpretation of Japanese guidance for
 use of biologics for PsA (the 2019 version)**

Toshiyuki YAMAMOTO
 (Fukushima Medical University)

December 26th, 2020

MCC号CXO20121585有效期2021-12-15, 资料过期, 视同作废.
